Toho : Notice Regarding the Revision of the Full-year Earnings Forecasts for the Fiscal Year Ended March 2024(142 KB)

	April 30, 2024
To whom it may concern:
Company Name	TOHO HOLDINGS CO., LTD.
Corporate	Atsushi Udoh, Representative Director, CEO
Representative
	(Prime Market of Tokyo Stock Exchange
Contact:	Securities Code: 8129)
Makoto Kawamura, Corporate Officer and
	General Manager, Corporate Communications
	and Investor Relations Division
	(TEL: [phone])

Notice Regarding the Revision of the Full-year Earnings Forecasts for the Fiscal Year Ended March 2024

TOHO HOLDINGS CO., LTD. is pleased to announce that, in the light of matters such as the recent trends in the Company's performance, it has revised its consolidated results forecasts for the fiscal year ended March 2024, which were announced on February 8, 2024, as below.

1. The Revision of the Full-year Earnings Forecasts for the Fiscal Year Ended March 2024 (From April 1, 2023 to March 31, 2024)

				Profit
	Net Sales	Operating Profit	Ordinary Profit	Attributable to	Net Income per
				Owners of	Share
				Parent
Previous forecast (A)	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
1,458,000	12,600	15,500	14,500	224.75
Revised forecast (B)	1,476,000	19,300	21,700	20,600	319.25
Increase/Decrease (B-A)	18,000	6,700	6,200	6,100
Change (%)	1.2	53.2	40.0	42.1
(Reference)
Result of FY ended March	1,392,117	16,365	19,176	13,630	196.70
2023

※From the first quarter of the fiscal year ended March 2024, the presentation method of information service fees, etc. has been changed from non-operating income to net sales, and the consolidated results of the previous fiscal year have been reclassified retrospectively.

2. Reason for the Revision

For the fiscal year under review, the Company announced the revision of its consolidated earnings forecast on

February 8, 2024. Even in the business environment following the announcement, net sales of specialty pharmaceuticals and other limited-handling products for selected wholesalers continued to increase. In addition, as a result of changes to the distribution arrangements at some pharmaceutical manufacturers, promotion of negotiations based on unit price considering individual product value and distribution cost, and the sale of investment securities, sales and profits in all categories are expected to exceed the previous forecast.

In light of the above, we have revised the full-year earnings forecasts for the fiscal year ended March 2024, which were announced on February 8, 2024.